Clinical experience with EPID dosimetry for prostate IMRT pre-treatment dose verification

AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA

PURPOSE

Electronic portal imaging devices (EPIDs) have been widely utilized for patient-specific quality assurance (PSQA) and their use for transit dosimetry applications is emerging. Yet there are no specific guidelines on the potential uses, limitations, and correct utilization of EPIDs for these purposes. The American Association of Physicists in Medicine (AAPM) Task Group 307 (TG-307) provides a comprehensive review of the physics, modeling, algorithms and clinical experience with EPID-based pre-treatment and transit dosimetry techniques. This review also includes the limitations and challenges in the clinical implementation of EPIDs, including recommendations for commissioning, calibration and validation, routine QA, tolerance levels for gamma analysis and risk-based analysis.

METHODS

Characteristics of the currently available EPID systems and EPID-based PSQA techniques are reviewed. The details of the physics, modeling, and algorithms for both pre-treatment and transit dosimetry methods are discussed, including clinical experience with different EPID dosimetry systems. Commissioning, calibration, and validation, tolerance levels and recommended tests, are reviewed, and analyzed. Risk-based analysis for EPID dosimetry is also addressed.

RESULTS

Clinical experience, commissioning methods and tolerances for EPID-based PSQA system are described for pre-treatment and transit dosimetry applications. The sensitivity, specificity, and clinical results for EPID dosimetry techniques are presented as well as examples of patient-related and machine-related error detection by these dosimetry solutions. Limitations and challenges in clinical implementation of EPIDs for dosimetric purposes are discussed and acceptance and rejection criteria are outlined. Potential causes of and evaluations of pre-treatment and transit dosimetry failures are discussed. Guidelines and recommendations developed in this report are based on the extensive published data on EPID QA along with the clinical experience of the TG-307 members.

CONCLUSION

TG-307 focused on the commercially available EPID-based dosimetric tools and provides guidance for medical physicists in the clinical implementation of EPID-based patient-specific pre-treatment and transit dosimetry QA solutions including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatments.

Deep learning-based 3Din vivodose reconstruction with an electronic portal imaging device for magnetic resonance-linear accelerators: a proof of concept study

Objective.To develop a novel deep learning-based 3Din vivodose reconstruction framework with an electronic portal imaging device (EPID) for magnetic resonance-linear accelerators (MR-LINACs).Approach.The proposed method directly back-projected 2D portal dose into 3D patient coarse dose, which bypassed the complicated patient-to-EPID scatter estimation step used in conventional methods. A pre-trained convolutional neural network (CNN) was then employed to map the coarse dose to the final accurate dose. The electron return effect caused by the magnetic field was captured with the CNN model. Patient dose and portal dose datasets were synchronously generated with Monte Carlo simulation for 96 patients (78 cases for training and validation and 18 cases for testing) treated with fixed-beam intensity-modulated radiotherapy in four different tumor sites, including the brain, nasopharynx, lung, and rectum. Beam angles from the training dataset were further rotated 2-3 times, and doses were recalculated to augment the datasets.Results.The comparison between reconstructed doses and MC ground truth doses showed mean absolute errors <0.88% for all tumor sites. The averaged 3Dγ-passing rates (3%, 2 mm) were 97.42%±2.66% (brain), 98.53%±0.95% (nasopharynx), 99.41%±0.46% (lung), and 98.63%±1.01% (rectum). The dose volume histograms and indices also showed good consistency. The average dose reconstruction time, including back projection and CNN dose mapping, was less than 3 s for each individual beam.Significance.The proposed method can be potentially used for accurate and fast 3D dosimetric verification for online adaptive radiotherapy using MR-LINACs.

An Empirical Transmitted EPID Dosimetry Method using a Back-Projection Algorithm

Background:

The present study aimed to introduce a rapid transmission dosimetry through an electronic portal-imaging device (EPID) to achieve two-dimensional (2D) dose distribution for homogenous environments.

Material and Methods:

In this Phantom study, first, the EPID calibration curve and correction coefficients for field size were obtained from EPID and ionization chamber. Second, the EPID off-axis pixel response was measured, and the grey-scale image of the EPID was converted into portal dose image using the calibration curve. Next, the scattering contribution was calculated to obtain the primary dose. Then, by means of a verified back-projection algorithm and the Scatter-to-Primary dose ratio, a 2D dose distribution at the mid-plane was obtained.

Results:

The results obtained from comparing the transmitted EPID dosimetry to the calculated dose, using commercial treatment planning system with gamma function while there is 3% dose difference and 3mm distance to agreement criteria, were in a good agreement. In addition, the pass rates of γ < 1 was 94.89% for the homogeneous volumes.

Conclusion:

Based on the results, the method proposed can be used in EPID dosimetry.

Technical Note: Alternating clinical usage of the integral quality monitor transmission detector

PURPOSE

The purpose of the study was the implementation of a method to use the integral quality monitor (IQM) transmission detector for occasional, alternating usage during patient treatment with intensity modulated radiotherapy. Due to attenuation, the transmission detector must be taken into account during the planning process. The proposed workflow is based on determining a dynamic transmission factor (dTF) required to scale the total number of MU of the original radiotherapy (RT) plan. Thus a very similar radiation therapy plan is obtained that can be used with the IQM detector.

METHODS

Ten clinically applied volumetric modulated arc therapy plans were delivered at two beam qualities. A dTF is calculated from each RT plan for which a collapsed RT plan was created for verification using a two-dimensional array with and without the IQM detector. The total number of MU of the original RT plan was scaled by the inverse of the dTF to obtain the modified RT plan for clinical use with the IQM detector. Validation was performed with an electronic three-dimensional phantom and via gamma analysis using strict criteria of 1%/1 mm.

RESULTS

Except for one outlier, the gamma pass rate between the original RT plan without IQM and the modified RT plan with IQM was always above 99.5%. The variations of the dTF were smaller than 1% for all tested RT plans.

CONCLUSIONS

The results show that the proposed workflow can be used clinically. Thus the IQM transmission detector can also be used occasionally for online verification of RT plans.

Commissioning and evaluation of a radiochromic EBT3 film dosimetry system

Purpose

This work reports our study to commission a radiochromic film dosimetry system using the timely EBT3 film. We carried out dosimetric evaluations on different characteristics of photon beams (e.g., flatness, symmetry and penumbra) in radiation dose delivery.

Materials and Methods

A Varian linear accelerator producing 6 and 15 MV photon beams with 120 multi-leaf collimator was used in this study. PTW ionisation chamber was used to measure the beam characteristics such as symmetry, flatness and penumbra and these measurements were used to commission the radiochormic EBT3 film dosimetry system. The results of irradiated films were analysed using the radiochromic film QA Pro software 2016.

Results

The measured film doses were analysed at two different colour channels (green and red) using two scanning geometries (i.e., upper or lower side of film facing the scanner light source) at two dose levels (10 and 40 Gy). The difference between the ionisation chamber and film results was found insignificant and within the acceptable range as per the World Health Organisation standard.

Conclusion

Results of the comparison between the ionisation chamber and film measurements show that our radiochormic EBT3 film dosimetry system is reliable and cost-effective in the output measurement of a linear accelerator. Our measurements confirm that our EBT3 film dosimetry agreed well with the ionisation chamber, and can be used as a re-validation tool for linear accelerator quality control.

Comparison of MLC error sensitivity of various commercial devices for VMAT pre-treatment quality assurance

The purpose of this study was to compare the MLC error sensitivity of various measurement devices for VMAT pre-treatment quality assurance (QA). This study used four QA devices (Scandidos Delta4, PTW 2D-array, iRT systems IQM, and PTW Farmer chamber). Nine retrospective VMAT plans were used and nine MLC error plans were generated for all nine original VMAT plans. The IQM and Farmer chamber were evaluated using the cumulative signal difference between the baseline and error-induced measurements. In addition, to investigate the sensitivity of the Delta4 device and the 2D-array, global gamma analysis (1%/1, 2%/2, and 3%/3 mm), dose difference (1%, 2%, and 3%) were used between the baseline and error-induced measurements. Some deviations of the MLC error sensitivity for the evaluation metrics and MLC error ranges were observed. For the two ionization devices, the sensitivity of the IQM was significantly better than that of the Farmer chamber (P < 0.01) while both devices had good linearly correlation between the cumulative signal difference and the magnitude of MLC errors. The pass rates decreased as the magnitude of the MLC error increased for both Delta4 and 2D-array. However, the small MLC error for small aperture sizes, such as for lung SBRT, could not be detected using the loosest gamma criteria (3%/3 mm). Our results indicate that DD could be more useful than gamma analysis for daily MLC QA, and that a large-area ionization chamber has a greater advantage for detecting systematic MLC error because of the large sensitive volume, while the other devices could not detect this error for some cases with a small range of MLC error.

Safety Considerations in Stereotactic Body Radiation Therapy

Although many error pathways are common to both stereotactic body radiation therapy (SBRT) and conventional radiation therapy, SBRT presents a special set of challenges including short treatment courses and high-doses, an enhanced reliance on imaging, technical challenges associated with commissioning, special resource requirements for staff and training, and workflow differences. Emerging data also suggest that errors occur at a higher rate in SBRT treatments. Furthermore, when errors do occur they often have a greater effect on SBRT treatments. Given these challenges, it is important to understand and employ systematic approaches to ensure the quality and safety of SBRT treatment. Here, we outline the pathways by which error can occur in SBRT, illustrated through a series of case studies, and highlight 9 specific well-established tools to either reduce error or minimize its effect to the patient or both.

Assessment of a 2D electronic portal imaging devices-based dosimetry algorithm for pretreatment and in-vivo midplane dose verification

Background:

The use of electronic portal imaging devices (EPIDs) is a method for the dosimetric verification of radiotherapy plans, both pretreatment and in vivo. The aim of this study is to test a 2D EPID-based dosimetry algorithm for dose verification of some plans inside a homogenous and anthropomorphic phantom and in vivo as well.

Materials and Methods:

Dose distributions were reconstructed from EPID images using a 2D EPID dosimetry algorithm inside a homogenous slab phantom for a simple 10 × 10 cm² box technique, 3D conformal (prostate, head-and-neck, and lung), and intensity-modulated radiation therapy (IMRT) prostate plans inside an anthropomorphic (Alderson) phantom and in the patients (one fraction in vivo) for 3D conformal plans (prostate, head-and-neck and lung).

Results:

The planned and EPID dose difference at the isocenter, on an average, was 1.7% for pretreatment verification and less than 3% for all in vivo plans, except for head-and-neck, which was 3.6%. The mean γ values for a seven-field prostate IMRT plan delivered to the Alderson phantom varied from 0.28 to 0.65. For 3D conformal plans applied for the Alderson phantom, all γ1% values were within the tolerance level for all plans and in both anteroposterior and posteroanterior (AP-PA) beams.

Conclusion:

The 2D EPID-based dosimetry algorithm provides an accurate method to verify the dose of a simple 10 × 10 cm² field, in two dimensions, inside a homogenous slab phantom and an IMRT prostate plan, as well as in 3D conformal plans (prostate, head-and-neck, and lung plans) applied using an anthropomorphic phantom and in vivo. However, further investigation to improve the 2D EPID dosimetry algorithm for a head-and-neck case, is necessary.

Quantifying the performance of in vivo portal dosimetry in detecting four types of treatment parameter variations

PURPOSE

To quantify the ability of electronic portal imaging device (EPID) dosimetry used during treatment (in vivo) in detecting variations that can occur in the course of patient treatment.

METHODS

Images of transmitted radiation from in vivo EPID measurements were converted to a 2D planar dose at isocenter and compared to the treatment planning dose using a prototype software system. Using the treatment planning system (TPS), four different types of variability were modeled: overall dose scaling, shifting the positions of the multileaf collimator (MLC) leaves, shifting of the patient position, and changes in the patient body contour. The gamma pass rate was calculated for the modified and unmodified plans and used to construct a receiver operator characteristic (ROC) curve to assess the detectability of the different parameter variations. The detectability is given by the area under the ROC curve (AUC). The TPS was also used to calculate the impact of the variations on the target dose-volume histogram.

RESULTS

Nine intensity modulation radiation therapy plans were measured for four different anatomical sites consisting of 70 separate fields. Results show that in vivo EPID dosimetry was most sensitive to variations in the machine output, AUC = 0.70 - 0.94, changes in patient body habitus, AUC = 0.67 - 0.88, and systematic shifts in the MLC bank positions, AUC = 0.59 - 0.82. These deviations are expected to have a relatively small clinical impact [planning target volume (PTV) D99 change <7%]. Larger variations have even higher detectability. Displacements in the patient's position and random variations in MLC leaf positions were not readily detectable, AUC < 0.64. The D99 of the PTV changed by up to 57% for the patient position shifts considered here.

CONCLUSIONS

In vivo EPID dosimetry is able to detect relatively small variations in overall dose, systematic shifts of the MLC's, and changes in the patient habitus. Shifts in the patient's position which can introduce large changes in the target dose coverage were not readily detected.

Clinical Experience and Evaluation of Patient Treatment Verification With a Transit Dosimeter

PURPOSE

To prospectively evaluate a protocol for transit dosimetry on a patient population undergoing intensity modulated radiation therapy (IMRT) and to assess the issues in clinical implementation of electronic portal imaging devices (EPIDs) for treatment verification.

METHODS AND MATERIALS

Fifty-eight patients were enrolled in the study. Amorphous silicon EPIDs were calibrated for dose and used to acquire images of delivered fields. Measured EPID dose maps were back-projected using the planning computed tomographic (CT) images to calculate dose at prespecified points within the patient and compared with treatment planning system dose offline using point dose difference and point γ analysis. The deviation of the results was used to inform future action levels.

RESULTS

Two hundred twenty-five transit images were analyzed, composed of breast, prostate, and head and neck IMRT fields. Patient measurements demonstrated the potential of the dose verification protocol to model dose well under complex conditions: 83.8% of all delivered beams achieved the initial set tolerance level of ΔD of 0 ± 5 cGy or %ΔD of 0% ± 5%. Importantly, the protocol was also sensitive to anatomic changes and spotted that 3 patients from 20 measured prostate patients had undergone anatomic change in comparison with the planning CT. Patient data suggested an EPID-reconstructed versus treatment planning system dose difference action level of 0% ± 7% for breast fields. Asymmetric action levels were more appropriate for inversed IMRT fields, using absolute dose difference (-2 ± 5 cGy) or summed field percentage dose difference (-6% ± 7%).

CONCLUSIONS

The in vivo dose verification method was easy to use and simple to implement, and it could detect patient anatomic changes that impacted dose delivery. The system required no extra dose to the patient or treatment time delay and so could be used throughout the course of treatment to identify and limit systematic and random errors in dose delivery for patient groups.

Feasibility of portal dosimetry for flattening filter-free radiotherapy

The feasibility of using portal dosimetry (PD) to verify 6 MV flattening filter‐free (FFF) IMRT treatments was investigated. An Elekta Synergy linear accelerator with an Agility collimator capable of delivering FFF beams and a standard iViewGT amorphous silicon (aSi) EPID panel (RID 1640 AL5P) at a fixed SSD of 160 cm were used. Dose rates for FFF beams are up to four times higher than for conventional flattened beams, meaning images taken at maximum FFF dose rate can saturate the EPID. A dose rate of 800 MU/min was found not to saturate the EPID for open fields. This dose rate was subsequently used to characterize the EPID for FFF portal dosimetry. A range of open and phantom fields were measured with both an ion chamber and the EPID, to allow comparison between the two. The measured data were then used to create a model within The Nederlands Kanker Instituut's (NKI's) portal dosimetry software. The model was verified using simple square fields with a range of field sizes and phantom thicknesses. These were compared to calculations performed with the Monaco treatment planning system (TPS) and isocentric ion chamber measurements. It was found that the results for the FFF verification were similar to those for flattened beams with testing on square fields, indicating a difference in dose between the TPS and portal dosimetry of approximately 1%. Two FFF IMRT plans (prostate and lung SABR) were delivered to a homogeneous phantom and showed an overall dose difference at isocenter of ∼0.5% and good agreement between the TPS and PD dose distributions. The feasibility of using the NKI software without any modifications for high‐dose‐rate FFF beams and using a standard EPID detector has been investigated and some initial limitations highlighted.

PACS number: 87.55.Qr

Sensitivity of an Elekta iView GT a-Si EPID model to delivery errors for pre-treatment verification of IMRT fields

A Monte Carlo model of an Elekta iViewGT amorphous silicon electronic portal imaging device (a-Si EPID) has been validated for pre-treatment verification of clinical IMRT treatment plans. The simulations involved the use of the BEAMnrc and DOSXYZnrc Monte Carlo codes to predict the response of the iViewGT a-Si EPID model. The predicted EPID images were compared to the measured images obtained from the experiment. The measured EPID images were obtained by delivering a photon beam from an Elekta Synergy linac to the Elekta iViewGT a-Si EPID. The a-Si EPID was used with no additional build-up material. Frame averaged EPID images were acquired and processed using in-house software. The agreement between the predicted and measured images was analyzed using the gamma analysis technique with acceptance criteria of 3 %/3 mm. The results show that the predicted EPID images for four clinical IMRT treatment plans have a good agreement with the measured EPID signal. Three prostate IMRT plans were found to have an average gamma pass rate of more than 95.0 % and a spinal IMRT plan has the average gamma pass rate of 94.3 %. During the period of performing this work a routine MLC calibration was performed and one of the IMRT treatments re-measured with the EPID. A change in the gamma pass rate for one field was observed. This was the motivation for a series of experiments to investigate the sensitivity of the method by introducing delivery errors, MLC position and dosimetric overshoot, into the simulated EPID images. The method was found to be sensitive to 1 mm leaf position errors and 10 % overshoot errors.

Accurate IMRT fluence verification for prostate cancer patients using 'in-vivo' measured EPID images and in-room acquired kilovoltage cone-beam CT scans

Background

To investigate for prostate cancer patients the comparison of ‘in-vivo’ measured portal dose images (PDIs) with predictions based on a kilovoltage cone-beam CT scan (CBCT), acquired during the same treatment fraction, as an alternative for pre-treatment verification. For evaluation purposes, predictions were also performed using the patients’ planning CTs (pCT).

Methods

To get reliable CBCT electron densities for PDI predictions, Hounsfield units from the pCT were mapped onto the CBCT, while accounting for non-rigidity in patient anatomy in an approximate way. PDI prediction accuracy was first validated for an anatomical phantom, using IMRT treatment plans of ten prostate cancer patients. Clinical performance was studied using data acquired for 50 prostate cancer patients. For each patient, 4–5 CBCTs were available, resulting in a total of 1413 evaluated images. Measured and predicted PDIs were compared using γ-analyses with 3% global dose difference and 3 mm distance to agreement as reference criteria. Moreover, the pass rate for automated PDI comparison was assessed. To quantify improvements in IMRT fluence verification accuracy results from multiple fractions were combined by generating a γ-image with values halfway the minimum and median γ values, pixel by pixel.

Results

For patients, CBCT-based PDI predictions showed a high agreement with measurements, with an average percentage of rejected pixels of 1.41% only. In spite of possible intra-fraction motion and anatomy changes, this was only slightly larger than for phantom measurements (0.86%). For pCT-based predictions, the agreement deteriorated (average percentage of rejected pixels 2.98%), due to an enhanced impact of anatomy variations. For predictions based on CBCT, combination of the first 2 fractions yielded gamma results in close agreement with pre-treatment analyses (average percentage of rejected pixels 0.63% versus 0.35%, percentage of rejected beams 0.6% versus 0%). For the pCT-based approach, only combination of the first 5 fractions resulted in acceptable agreement with pre-treatment results.

Conclusion

In-room acquired CBCT scans can be used for high accuracy IMRT fluence verification based on in-vivo measured EPID images. Combination of γ results for the first 2 fractions can largely compensate for small accuracy reductions, with respect to pre-treatment verification, related to intra-fraction motion and anatomy changes.

A Monte Carlo study on electron and neutron contamination caused by the presence of hip prosthesis in photon mode of a 15 MV Siemens PRIMUS linac

Several investigators have pointed out that electron and neutron contamination from high‐energy photon beams are clinically important. The aim of this study is to assess electron and neutron contamination production by various prostheses in a high‐energy photon beam of a medical linac. A 15 MV Siemens PRIMUS linac was simulated by MCNPX Monte Carlo (MC) code and the results of percentage depth dose (PDD) and dose profile values were compared with the measured data. Electron and neutron contaminations were calculated on the beam's central axis for Co‐Cr‐Mo, stainless steel, Ti‐alloy, and Ti hip prostheses through MC simulations. Dose increase factor (DIF) was calculated as the ratio of electron (neutron) dose at a point for 10×10 cm2 field size in presence of prosthesis to that at the same point in absence of prosthesis. DIF was estimated at different depths in a water phantom. Our MC‐calculated PDD and dose profile data are in good agreement with the corresponding measured values. Maximum dose increase factor for electron contamination for Co‐Cr‐Mo, stainless steel, Ti‐alloy, and Ti prostheses were equal to 1.18, 1.16, 1.16, and 1.14, respectively. The corresponding values for neutron contamination were respectively equal to: 184.55, 137.33, 40.66, and 43.17. Titanium‐based prostheses are recommended for the orthopedic practice of hip junction replacement. When treatment planning for a patient with hip prosthesis is performed for a high‐energy photon beam, attempt should be made to ensure that the prosthesis is not exposed to primary photons.

PACS numbers: 87.56.bd, 87.55.kh, 87.55.Gh

[Electronic portal image device dosimetry for volumetric modulated arc therapy]

Recently electronic portal image devices (EPIDs) have been widely used for quality assurance and dose verification. However there are no reports describing EPID dosimetry for Elekta volumetric modulated arc therapy (VMAT). We have investigated EPID dosimetry during VMAT delivery using a commercial software EPIDose with an Elekta Synergy linac. Dose rate dependence and the linac system sag during gantry rotation were measured. Gamma indices were calculated between measured doses using an EPID and calculation made by a treatment planning system for prostate VMAT test plans. The results were also compared to gamma indices using films and a two-dimensional detector array, MapCHECK2. The pass rates of the gamma analysis with a criterion of 3% and 2 mm for the three methods were over 96% with good consistency. Our results have showed that EPID dosimetry is feasible for Elekta VMAT.

Gantry angle-dependent correction of dose detection error due to panel position displacement in IMRT dose verification using EPIDs

PURPOSE

The purpose of this study was to measure the mechanical position displacement of three types of electronic portal image device (EPID) panels at different gantry angles and evaluate the impact of positional displacement on intensity modulated radiation therapy (IMRT) dose verification using an EPID.

METHODS

Three types of linear accelerators and EPIDs (aS500, aS1000 and iViewGT) were used. The portal images were taken every 10° within 360° range. The position coordinate difference between the panel center and the portal film center at different gantry angles was measured, then the mechanical position displacement of EPIDs dependent on the gantry angles was analyzed. For the three linear accelerators and EPIDs, five IMRT plans were measured using EPIDs at 0° gantry angel and at the actual treatment angles. The Gamma technique was used to evaluate the resulted dose difference before and after the corrections of the position displacement by a in-house software.

RESULTS

For aS500, aS1000 and iViewGT, the maximum mechanical position displacement was 2.9 ± 0.1 mm, 0.2 ± 0.1 mm and 0.1 ± 0.3 mm in the lateral direction and -4.2 ± 0.2 mm, -4.2 ± 0.1 mm and -2.2 ± 0.1 mm in the longitudinal direction, respectively. The position displacement in the longitudinal direction of the three EPIDs can be fitted well with a function. For aS500, aS1000 and iViewGT, the 3%/3 mm gamma pass rates were increased by 6.7%, 2.9% and 0.1% after displacement corrections; and while the 2%/2 mm gamma pass rates were increased by 11.2%, 8.1% and 1.6%. After the displacement correction, there was a slight gamma pass rate difference between the fixed zero degree gantry and the actual treatment angles.

CONCLUSION

When the EPIDs were used for IMRT dose verification, there was occasionally large EPID mechanical position displacement, which should be corrected.

Modification of the gamma function for the recognition of over- and under-dose regions in three dimensions

In order to evaluate two-dimensional radiation dose distributions, an algorithm called the Gamma function has recently been modified. The current study concentrates on modification of the gamma function as a three-dimensional dose distribution evaluation tool, and includes the recognition of over-dose/under-dose areas. Using a sign term, the conventional gamma function separates the disagreed areas into two parts: over-dose and under-dose areas. The new gamma function was modified using an extension of the dose difference criterion, ΔD, from two dimensions into three dimensions. In order to provide two-dimensional dose maps for analysis, several images were acquired for a range of regular and irregular radiation fields using a Scanning Liquid Ionization Chamber Electronic Portal Imaging Device. The raw images were then converted into two-dimensional transmitted dose maps using an empirical method. They were utilized as reference dose maps. Translational and rotational manipulations were performed on the reference dose distribution maps to provide evaluated dose maps. The reference and evaluated dose maps were then compared using conventional and modified gamma tools. The results indicated that the modified algorithm is able to enhance the over- and under-dose regions. In addition, a slight increase of the agreement percentage for reference and evaluated dose maps were observed by the extension of ΔD to three dimensions. It is concluded that the modified method is more realistic and applicable for the evaluation of both two-dimensional and three-dimensional dose distributions.

2D lag and signal nonlinearity correction in an amorphous silicon EPID and their impact on pretreatment dosimetric verification

PURPOSE

This investigation provides measurements of signal lag and nonlinearity separately for the Varian aS500 electronic portal imaging device (EPID), and an algorithm to correct for these effects in 2D; their potential impact on intensity modulated radiation therapy (IMRT) verification is also investigated. The authors quantify lag, as a function of both delivered monitor units (MU) and time, by using a range of MUs delivered at a clinically used rate of 400 MU∕min. Explicit cumulative lag curves are thus determined for a range of MUs and times between the end of irradiation and the end of image acquisition. Signal nonlinearity is also investigated as a function of total MUs delivered. The family of cumulative lag curves and signal nonlinearity are then used to determine their effects on dynamic multileaf collimator (MLC) (IMRT) deliveries, and to correct for theses effects in 2D.

METHODS

Images acquired with an aS500 EPID and Varis Portal-Vision software were used to quantify detector lag and signal-nonlinearity. For the signal lag investigation, Portal-Vision's service monitor was used to acquire EPID images at a rate of 8 frames/s. The images were acquired during irradiation and 66 s thereafter, by inhibiting the M-holdoff-In signal of the Linac for a range of 4.5-198.5 MUs. Relative cumulative lag was calculated by integrating the EPID signal for a time after beam-off, and normalizing this to the integrated EPID signal accumulated during radiation. Signal nonlinearity was studied by acquiring 10 × 10 cm(2) open-field EPID images in "integrated image" mode for a range of 2-500 MUs, and normalized to the 100 MU case. All data were incorporated into in-house written software to create a 2D correction map for these effects, using the field's MLC file and a field-specific calculated 2D "time-map," which keeps track of the time elapsed from the last fluence delivered at each given point in the image to the end of the beam delivery.

RESULTS

Relative cumulative lag curves reveal that the lag alone can deviate the EPID's perceived dose by as large as 6% (1 MU delivery, 60 s postirradiation). For signal nonlinearity relative to 100 MU, EPID signals per MU of 0.84 and 1.01 were observed for 2 and 500 MUs, respectively. Correction maps were applied to a 1 cm sweeping-window 14 × 14 cm(2) field and clinical head-and-neck IMRT field. A mean correction of 1.028 was implemented in the head-and-neck field, which significantly reduced lag-related asymmetries in the EPID images, and restored linearity to the EPID imager's dose response. Corrections made to the sweeping-field showed good agreement with the treatment planning system-predicted field, yielding an average percent difference of 0.05% ± 0.91%, compared to the -1.32% ± 1.02% before corrections, or 1.75% ± 1.04% when only a signal nonlinearity correction is made.

CONCLUSIONS

Lag and signal-nonlinearity have been quantified for an aS500 EPID imager, and an effective 2D correction method has been developed which effectively removes nonlinearity and lag effects. Both of these effects were shown to negatively impact IMRT verifications. Especially fields that involve prolonged irradiation and small overall MUs should be corrected for in 2D.

Feasibility of a remote, automated daily delivery verification of volumetric-modulated arc therapy treatments using a commercial record and verify system

Volumetric‐modulated arc therapy (VMAT) is an effective but complex technique for delivering radiation therapy. VMAT relies on precise combinations of dose rate, gantry speed, and multileaf collimator (MLC) shapes to deliver intensity‐modulated patterns. Such complexity warrants the development of correspondingly robust performance verification systems. In this work, we report on a remote, automated software system for daily delivery verification of VMAT treatments. The performance verification software system consists of three main components: (1) a query module for retrieving daily MLC, gantry, and jaw positions reported by the linear accelerator control system to the record and verify system; (2) an analysis module which reads the daily delivery report generated from the database query module, compares the reported treatment positions against the planned positions, and compiles delivery position error reports; and (3) a graphical reporting module which displays reports initiated by a user anywhere within the institutional network or which can be configured to alert authorized users when predefined tolerance values are exceeded. The utility of the system was investigated through analysis of patient data collected at our clinic. Nearly 2500 VMAT fractions have been analyzed with the delivery verification system at our institution. The average percentage of reported MLC leaf positions within 3 mm, gantry positions within 2°, and jaw positions within 3 mm of their planned positions was 92.9%±5.5%,95.9%±2.9%, and 99.7%±0.6%, respectively. The level of agreement between planned and reported MLC positions decreased for treatment plans requiring larger MLC leaf movements between control points. Differences in the reported MLC position error between the delivery verification system and data extracted manually from the control system were noted; however, the differences are likely systematic and, therefore, may be characterized if appropriately accounted for. Further investigation is needed to confirm the utility and accuracy of the system.

PACS numbers: 87.55.N‐, 87.55.T‐, 87.55.Qr

Exit fluence analysis using portal dosimetry in volumetric modulated arc therapy

AIM

In measuring exit fluences, there are several sources of deviations which include the changes in the entrance fluence, changes in the detector response and patient orientation or geometry. The purpose of this work is to quantify these sources of errors.

BACKGROUND

The use of the volumetric modulated arc therapy treatment with the help of image guidance in radiotherapy results in high accuracy of delivering complex dose distributions while sparing critical organs. The transit dosimetry has the potential of Verifying dose delivery by the linac, Multileaf collimator positional accuracy and the calculation of dose to a patient or phantom.

MATERIALS AND METHODS

The quantification of errors caused by a machine delivery is done by comparing static and arc picket fence test for 30 days. A RapidArc plan, created for the pelvis site was delivered without and with Rando phantom and exit portal images were acquired. The day to day dose variation were analysed by comparing the daily exit dose images during the course of treatment. The gamma criterion used for analysis is 3% dose difference and 3 mm distance to agreement with a threshold of 10% of maximum dose.

RESULTS

The maximum standard deviation for the static and arc picket fence test fields were 0.19 CU and 1.3 CU, respectively. The delivery of the RapidArc plans without a phantom shows the maximum standard deviation of 1.85 CU and the maximum gamma value of 0.59. The maximum gamma value for the RapidArc plan delivered with the phantom was found to be 1.2. The largest observed fluence deviation during the delivery to patient was 5.7% and the maximum standard deviation was 4.1 CU.

CONCLUSION

It is found from this study that the variation due to patient anatomy and interfraction organ motion is significant.

A study on dosimetric properties of electronic portal imaging device and its use as a quality assurance tool in Volumetric Modulated Arc Therapy

AIM

In this study, the dosimetric properties of the electronic portal imaging device were examined and the quality assurance testing of Volumetric Modulated Arc Therapy was performed.

BACKGROUND

RapidArc involves the variable dose rate, leaf speed and the gantry rotation. The imager was studied for the effects like dose, dose rate, field size, leaf speed and sag during gantry rotation.

MATERIALS AND METHODS

A Varian RapidArc machine equipped with 120 multileaf collimator and amorphous silicon detector was used for the study. The characteristics that are variable in RapidArc treatment were studied for the portal imager. The accuracy of a dynamic multileaf collimator position at different gantry angles and during gantry rotation was examined using the picket fence test. The control of the dose rate and gantry speed was verified using a test field irradiating seven strips of the same dose with different dose rate and gantry speeds. The control over leaf speed during arc was verified by irradiating four strips of different leaf speeds with the same dose in each strip. To verify the results, the RapidArc test procedure was compared with the X-Omat film and verified for a period of 6 weeks using EPID.

RESULTS

The effect of gantry rotation on leaf accuracy was minimal. The dose in segments showed good agreement with mean deviation of 0.8% for dose rate control and 1.09% for leaf speed control over different gantry speeds.

CONCLUSION

The results provided a precise control of gantry speed, dose rate and leaf speeds during RapidArc delivery and were consistent over 6 weeks.

Advances in radiation therapy dosimetry

During the last decade, there has been an explosion of new radiation therapy planning and delivery tools. We went through a rapid transition from conventional three-dimensional (3D) conformal radiation therapy to intensity-modulated radiation therapy (IMRT) treatments, and additional new techniques for motion-adaptive radiation therapy are being introduced. These advances push the frontiers in our effort to provide better patient care; and with the addition of IMRT, temporal dimensions are major challenges for the radiotherapy patient dosimetry and delivery verification. Advanced techniques are less tolerant to poor implementation than are standard techniques. Mis-administrations are more difficult to detect and can possibly lead to poor outcomes for some patients. Instead of presenting a manual on quality assurance for radiation therapy, this manuscript provides an overview of dosimetry verification tools and a focused discussion on breath holding, respiratory gating and the applications of four-dimensional computed tomography in motion management. Some of the major challenges in the above areas are discussed.

A generalized calibration procedure for in vivo transit dosimetry using siemens electronic portal imaging devices

A practical and accurate generalized in vivo dosimetry procedure has been implemented for Siemens linacs supplying 6, 10, and 15 MV photon beams, equipped with aSi electronic portal imaging devices (EPIDs). The in vivo dosimetry method makes use of correlation ratios between EPID transit signal, s (t) (0) (TPR,w,L), and phantom mid-plane dose, D (0)(TPR,w,L), as functions of phantom thickness, w, square field dimensions, L, and tissue-phantom ratio TPR(20,10). The s (t) (0) (TPR,w,L) and D (0)(TPR,w,L) values were defined to be independent of the EPID sensitivity and monitor unit calibration, while their dependence on TPR(20,10) was investigated to determine a set of generalized correlation ratios to be used for beams with TPR(20,10) falling in the examined range. This way, other radiotherapy centers can use the method with no need to locally perform the whole set of measurements in solid water phantoms, required to implement it. Tolerance levels for 3D conformal treatments, ranging between ±5 and ±6% according to tumor type and location, were estimated for comparison purposes between reconstructed isocenter dose, D (iso), and treatment planning system (TPS) computed dose D (iso,TPS). Finally a dedicated software, interfaceable with record and verify (R&V) systems used in the centers, was developed to obtain in vivo dosimetry results in less than 2 min after beam delivery.

Practical guidelines for routine intensity-modulated radiotherapy verification: pre-treatment verification with portal dosimetry and treatment verification with in vivo dosimetry

The purpose of this work is to provide guidelines for the routine use of portal dosimetry and in vivo diode measurements to verify intensity-modulated radiotherapy (IMRT) treatments. To achieve tolerance levels that are sensitive enough to intercept problems, both the portal dosimetry and the in vivo procedure must be optimised. Portal dosimetry was improved by the introduction of an optimised two-dimensional (2D) profile correction, which also accounted for the effect of backscatter from the R-arm. The scaled score, indicating the fraction of points not meeting the desired gamma evaluation criteria within the field opening, was determined as the parameter of interest. Using gamma criteria of a 3% dose difference and 3 mm distance to agreement, a "scaled score" threshold value of 1.5% was chosen to indicate excessive tongue and groove and other problems. The pre-treatment portal dosimetry quality assurance (QA) does not encompass verification of the patient dose calculation or position, and so it is complemented by in vivo diode measurements. Diode positioning is crucial in IMRT, and so we describe a method for diode positioning at any suitable point. We achieved 95% of IMRT field measurements within ±5% and 99% within ±8%, with improved accuracy being achieved over time owing to better positioning. Although the careful preparation and setup of the diode measurements can be time-consuming, this is compensated for by the time efficiency of the optimised procedure. Both methods are now easily absorbed into the routine work of the department.

Reduction of the effect of non-uniform backscatter from an E-type support arm of a Varian a-Si EPID used for dosimetry

Backscatter from the metallic components in the support arm is one of the sources of inaccuracy in dosimetry with Varian amorphous silicon electronic portal imaging devices (a-Si EPIDs). In this study, the non-uniform arm backscatter is blocked by adding lead sheets between the EPID and an E-type support arm. By comparing the EPID responses on and off the arm, with and without lead and considering the extra weight on the imager, 2 mm of lead was determined as the optimum thickness for both 6 and 18 MV beam energies. The arm backscatter at the central axis with the 2 mm lead in place decreased to 0.1% and 0.2% for the largest field size of 30 × 30 cm(2) using 6 and 18 MV beams, from 2.3% and 1.3% without lead. Changes in the source-to-detector distance (SDD) did not affect the backscatter component more than 1%. The symmetry of the in-plane profiles improved for all field sizes for both beam energies. The addition of lead decreased the contrast-to-noise ratio and resolution by 1.3% and 0.84% for images taken in 6 MV and by 0.5% and 0.38% for those in 18 MV beams. The displacement of the EPID central pixel was measured during a 360° gantry rotation with and without lead which was 1 pixel different. While the backscatter reduces with increasing lead thickness, a 2 mm lead sheet seems sufficient for acceptable dosimetry results without any major degradation to the routine performance of the imager. No increase in patient skin dose was detected.

Portal dosimetry for pretreatment verification of IMRT plan: a comparison with 2D ion chamber array

Portal dosimetry (PD) was performed for 181 fields from 14 IMRT plans of various clinical sites at gantry zero and source‐to‐detector distance (SDD) of 100 cm. PD was realized using aSi1000 electronic portal imaging device (EPID) and portal dose prediction (PDP) algorithm implemented in Eclipse treatment planning system (TPS). Agreement of PDP predicted and EPID measured photon fluence/dose distribution were evaluated using gamma (γ) index set at 3% at 3 mm distance to point agreement (DTA). Three gamma scaling parameters, maximum γ(γ)max, average γ(γ)avg and percentage of points with γ≤1(γ%≤1) were estimated for each field. An independent measurement was carried out using MatriXX 2D ion chamber array with detector plane at 100 cm and γmax,γavg and γ%≤1 were estimated using OmniPro IMRT analyzing software. Effect of extended SDD and gantry rotation on portal dosimetry outcome was also investigated for another 45 IMRT fields. PDP predicted and EPID measured photon fluence agrees well with overall mean values of γmax,γavg and γ%≤1 1 at 2.02, 0.24 and 99.43%, respectively. γ(γ)max value was lower in 15 MV compared to 6 MV IMRT plan. Independent verification using MatriXX showed comparable overall mean values of γ(γ)avg and γ%≤1 at 0.25 and 99.80%. However, in all plans, MatriXX showed significantly lower γmax(p<0.05) with an overall mean value of 1.35. In portal dosimetry, compared to gamma values at 100 cm SDD, γmax,γavg and γ%≤1 values improve from a mean of 0.16, 0.03 and 0.26 at 110 cm SDD to 0.35, 0.05 and 0.29 at 140 cm SDD. PD outcome was independent of gantry rotation. In conclusion, both MatriXX 2D ion chamber array and portal dosimetry showed comparable results and can be use as an alternative to each other for relative photon fluence verification.

PACS number (s): 87.55.D‐, 87.55.de, 87.55.kd,87.55.km,87.55.Qr,87.56Fc:

Monte Carlo-based adaptive EPID dose kernel accounting for different field size responses of imagers

The aim of this study is to present an efficient method to generate imager-specific Monte Carlo (MC)-based dose kernels for amorphous silicon-based electronic portal image device dose prediction and determine the effective backscattering thicknesses for such imagers. EPID field size-dependent responses were measured for five matched Varian accelerators from three institutions with 6 MV beams at the source to detector distance (SDD) of 105 cm. For two imagers, measurements were made with and without the imager mounted on the robotic supporting arm. Monoenergetic energy deposition kernels with 0-2.5 cm of water backscattering thicknesses were simultaneously computed by MC to a high precision. For each imager, the backscattering thickness required to match measured field size responses was determined. The monoenergetic kernel method was validated by comparing measured and predicted field size responses at 150 cm SDD, 10 x 10 cm2 multileaf collimator (MLC) sliding window fields created with 5, 10, 20, and 50 mm gaps, and a head-and-neck (H&N) intensity modulated radiation therapy (IMRT) patient field. Field size responses for the five different imagers deviated by up to 1.3%. When imagers were removed from the robotic arms, response deviations were reduced to 0.2%. All imager field size responses were captured by using between 1.0 and 1.6 cm backscatter. The predicted field size responses by the imager-specific kernels matched measurements for all involved imagers with the maximal deviation of 0.34%. The maximal deviation between the predicted and measured field size responses at 150 cm SDD is 0.39%. The maximal deviation between the predicted and measured MLC sliding window fields is 0.39%. For the patient field, gamma analysis yielded that 99.0% of the pixels have gamma < 1 by the 2%, 2 mm criteria with a 3% dose threshold. Tunable imager-specific kernels can be generated rapidly and accurately in a single MC simulation. The resultant kernels are imager position independent and are able to predict fields with varied incident energy spectra and a H&N IMRT patient field. The proposed adaptive EPID dose kernel method provides the necessary infrastructure to build reliable and accurate portal dosimetry systems.

Measurement-based Monte Carlo dose calculation system for IMRT pretreatment and on-line transit dose verifications

The aim of this study was to develop a dose simulation system based on portal dosimetry measurements and the BEAM Monte Carlo code for intensity-modulated (IM) radiotherapy dose verification. This measurement-based Monte Carlo (MBMC) system can perform, within one systematic calculation, both pretreatment and on-line transit dose verifications. BEAMnrc and DOSXYZnrc 2006 were used to simulate radiation transport from the treatment head, through the patient, to the plane of the aS500 electronic portal imaging device (EPID). In order to represent the nonuniform fluence distribution of an IM field within the MBMC simulation, an EPID-measured efficiency map was used to redistribute particle weightings of the simulated phase space distribution of an open field at a plane above a patient/phantom. This efficiency map was obtained by dividing the measured energy fluence distribution of an IM field to that of an open field at the EPID plane. The simulated dose distribution at the midplane of a homogeneous polystyrene phantom was compared to the corresponding distribution obtained from the Eclipse treatment planning system (TPS) for pretreatment verification. It also generated a simulated transit dose distribution to serve as the on-line verification reference for comparison to that measured by the EPID. Two head-and-neck (NPC1 and NPC2) and one prostate cancer fields were tested in this study. To validate the accuracy of the MBMC system, film dosimetry was performed and served as the dosimetry reference. Excellent agreement between the film dosimetry and the MBMC simulation was obtained for pretreatment verification. For all three cases tested, gamma evaluation with 3%/3 mm criteria showed a high pass percentage (> 99.7%) within the area in which the dose was greater than 30% of the maximum dose. In contrast to the TPS, the MBMC system was able to preserve multileaf collimator delivery effects such as the tongue-and-groove effect and interleaf leakage. In the NPC1 field, the TPS showed 16.5% overdose due to the tongue-and-groove effect and 14.6% overdose due to improper leaf stepping. Similarly, in the NPC2 field, the TPS showed 14.1% overdose due to the tongue-and-groove effect and 8.9% overdose due to improper leaf stepping. In the prostate cancer field, the TPS showed 6.8% overdose due to improper leaf stepping. No tongue-and-groove effect was observed for this field. For transit dose verification, agreements among the EPID measurement, the film dosimetry, and the MBMC system were also excellent with a minimum gamma pass percentage of 99.6%.

Characterization and clinical evaluation of a novel IMRT quality assurance system

Intensity-modulated radiation therapy (IMRT) is a complex procedure that involves the delivery of complex intensity patterns from various gantry angles. Due to the complexity of the treatment plans, the standard-of-care is to perform measurement based patient-specific quality assurance (QA). IMRT QA is traditionally done with film for relative dose in a plane and an ion chamber for absolute dose. This is a laborious and time-consuming process. In this work, we characterized, commissioned, and evaluated the QA capabilities of a novel commercial IMRT device Delta4, (Scandidos, Uppsala, Sweden). This device consists of diode matrices in 2 orthogonal planes inserted in a cylindrical acrylic phantom that is 22 cm in diameter. Although the system has detectors in only 2 planes, it provides a novel interpolation algorithm that is capable of estimating doses at points where no detectors are present. Each diode is sampled per beam pulse so that the dose distribution can be evaluated on segment-by-segment, beam-by-beam, or as a composite plan from a single set of measurements. The end user can calibrate the system to perform absolute dosimetry eliminating the need for additional ion chamber measurements. The patient's IMRT plan is imported into the device over the hospital LAN and the results of measurements can be displayed as gamma profiles, distance-to-agreement maps, dose difference maps, or the measured dose distribution can be superimposed of the patient's anatomy to display an as-delivered plan. We evaluated the system's reproducibility, stability, pulse-rate dependence, dose-rate dependence, angular dependence, linearity of dose response and energy response using carefully planned measurements. We also validated the system's interpolation algorithm by measuring a complex dose distribution from an IMRT treatment. Several simple and complex isodose distributions planned using a treatment planning system were delivered to the QA device; the planned and measured dose distributions were then compared and analyzed. In addition, the dose distributions measured by conventional IMRT QA, which uses an ion chamber and film, were compared. We found that this device is accurate and reproducible and that its interpolation algorithm is valid. In addition the supplied software and network interface allow a streamlined IMRT QA process.

Dosimetric verification of RapidArc treatment delivery

PURPOSE

Recently, Varian Medical Systems have announced the introduction of a new treatment technique, in which dose is delivered over a single gantry rotation with variable MLC positions, dose rate and gantry speed. In February 2008, a preclinical installation of the RapidArc beam delivery approach was carried out on a Varian Clinac at Rigshospitalet in Copenhagen. The purpose of the installation was to perform measurements to verify the correctness of doses delivered with the RapidArc technique. In May 2008, the clinical release of the RapidArc application was installed at Rigshospitalet.

METHODS AND MATERIALS

Nine treatment plans were generated in the Eclipse version 8.5 including the RapidArc optimizer for H&N and prostate cases. The plans were delivered to the Scandidos Delta4 cylindrical diode array phantom. First, the measured dose distributions were compared with the calculated doses. All plans were then delivered several times to verify consistency of the delivery. Gamma analysis was used to verify the correspondence between dose distributions. The temporal resolution of the delivery was analysed by investigating the arc segments between control points separately.

RESULTS

Overall, good agreement was observed between measured and calculated doses in most cases with gamma values above 1 in >95% of measured points. The reproducibility of delivery was also very high. Gamma analysis between two consecutive runs of the same delivery plan generally showed gamma values above 1 in none of the measured points, and dose deviation less than 1%. Temporal analysis showed small discrepancies between doses delivered between control points (approximately 2 degrees of the rotation) in consecutive runs of a plan, however these were cancelled out in the accumulated dose.

CONCLUSION

The delivery of RapidArc beam delivery has been verified to correspond well with calculated dose distributions for a number of different cases. The delivery was very reproducible, and was carried out with high stability of the accelerator performance.